Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
ConditionHematologic Malignancies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAsmaa Hassan mohamed Abdel Mawjoud
About this trial
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with hematologic malignancies.
Newly diagnosed
Disqualifiers
Patients with hematologic disorders other than hematologic malignancies.
Trial population
Patients with hematologic malignancies Newly diagnosed
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
CD56
Diagnostic testdetection of CD56 by flow cytometry
Treatment groups
38 Participants
are divided into 2 treatment groupsGroup A: control cases1 intervention
Group B: Patients1 intervention
Trial outcomes
Primary outcomes
1
To identify the Pattern of expression of CD56 in hematologic malignancies.
Expression of aberrant CD56 in hematologic malignancies by flowcytometry. To explore incidence of Expression of aberrant CD56 in hematologic malignancies . Correlation between this expression and outcome of the patient.
Time frame
1 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Asmaa Hassan mohamed Abdel Mawjoud
Lead sponsor
Assiut University
Sponsor institution
Source ClinicalTrials.gov